CN102695701B - Mglu2激动剂 - Google Patents

Mglu2激动剂 Download PDF

Info

Publication number
CN102695701B
CN102695701B CN201080058183.2A CN201080058183A CN102695701B CN 102695701 B CN102695701 B CN 102695701B CN 201080058183 A CN201080058183 A CN 201080058183A CN 102695701 B CN102695701 B CN 102695701B
Authority
CN
China
Prior art keywords
amino
hexane
compound
bicyclo
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080058183.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102695701A (zh
Inventor
J·A·莫恩
L·普列托
L.塔博阿达马蒂内兹
C·蒙特罗萨加多
B·W·肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102695701(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102695701A publication Critical patent/CN102695701A/zh
Application granted granted Critical
Publication of CN102695701B publication Critical patent/CN102695701B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201080058183.2A 2009-12-21 2010-12-15 Mglu2激动剂 Active CN102695701B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
EP09382290.6 2009-12-21
US30523910P 2010-02-17 2010-02-17
US61/305,239 2010-02-17
PCT/US2010/060371 WO2011084437A1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (2)

Publication Number Publication Date
CN102695701A CN102695701A (zh) 2012-09-26
CN102695701B true CN102695701B (zh) 2014-10-01

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080058183.2A Active CN102695701B (zh) 2009-12-21 2010-12-15 Mglu2激动剂

Country Status (35)

Country Link
US (1) US8318184B2 (enExample)
EP (1) EP2516406B1 (enExample)
JP (1) JP5779190B2 (enExample)
KR (1) KR101395356B1 (enExample)
CN (1) CN102695701B (enExample)
AR (1) AR079343A1 (enExample)
AU (1) AU2010340039B2 (enExample)
BR (1) BR112012017188B1 (enExample)
CA (1) CA2784667C (enExample)
CR (1) CR20120322A (enExample)
CY (1) CY1114880T1 (enExample)
DK (1) DK2516406T3 (enExample)
DO (1) DOP2012000173A (enExample)
EA (1) EA020229B1 (enExample)
EC (1) ECSP12011989A (enExample)
ES (1) ES2435651T3 (enExample)
HN (1) HN2012001160A (enExample)
HR (1) HRP20131052T1 (enExample)
IL (1) IL220011A (enExample)
JO (1) JO2978B1 (enExample)
MA (1) MA33824B1 (enExample)
MX (1) MX2012007332A (enExample)
MY (1) MY160618A (enExample)
NZ (1) NZ600305A (enExample)
PE (1) PE20121688A1 (enExample)
PH (1) PH12012501253A1 (enExample)
PL (1) PL2516406T3 (enExample)
PT (1) PT2516406E (enExample)
RS (1) RS53063B (enExample)
SG (1) SG181836A1 (enExample)
SI (1) SI2516406T1 (enExample)
TN (1) TN2012000281A1 (enExample)
TW (1) TWI477490B (enExample)
UA (1) UA107684C2 (enExample)
WO (1) WO2011084437A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2540728T1 (sl) 2010-02-17 2019-06-28 Takeda Pharmaceutical Company Limited Heterociklična spojina
KR101554793B1 (ko) * 2010-11-18 2015-09-21 일라이 릴리 앤드 캄파니 mGluR 2／3 길항제로서의 4-치환된-3-벤질옥시-비시클로［3.1.0］헥산 화합물
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
CA2836485C (en) 2011-06-17 2016-12-13 Eli Lilly And Company Bicyclo (3.1.0) hexane- 2,6 -dicarboxylic acid derivatives as mglu2 receptor agonist
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
PT3096790T (pt) 2014-01-21 2019-10-15 Janssen Pharmaceutica Nv Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso
EA202192105A3 (ru) 2014-02-04 2022-02-28 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
SG11201707994UA (en) 2015-04-01 2017-10-30 Akebia Therapeutics Inc Compositions and methods for treating anemia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1108240A (zh) * 1993-12-03 1995-09-13 伊莱利利公司 兴奋性氨基酸受体拮抗剂
WO1997017952A1 (en) * 1995-11-16 1997-05-22 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2003104217A2 (en) * 2002-06-01 2003-12-18 Eli Lilly And Company Prodrugs of excitatory amino acids
US7038077B2 (en) * 2001-01-11 2006-05-02 Eli Lilly And Company Prodrugs of excitatory amino acids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
CN1267407C (zh) * 2001-01-11 2006-08-02 伊莱利利公司 兴奋性氨基酸前体药物
EP1370519A1 (en) * 2001-02-22 2003-12-17 Eli Lilly And Company Synthetic excitatory amino acids
JP4984529B2 (ja) * 2003-06-26 2012-07-25 大正製薬株式会社 ２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体
KR101554793B1 (ko) * 2010-11-18 2015-09-21 일라이 릴리 앤드 캄파니 mGluR 2／3 길항제로서의 4-치환된-3-벤질옥시-비시클로［3.1.0］헥산 화합물
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1108240A (zh) * 1993-12-03 1995-09-13 伊莱利利公司 兴奋性氨基酸受体拮抗剂
WO1997017952A1 (en) * 1995-11-16 1997-05-22 Eli Lilly And Company Excitatory amino acid receptor antagonists
CN1207678A (zh) * 1995-11-16 1999-02-10 伊莱利利公司 兴奋性的氨基酸受体拮抗剂
US7038077B2 (en) * 2001-01-11 2006-05-02 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2003104217A2 (en) * 2002-06-01 2003-12-18 Eli Lilly And Company Prodrugs of excitatory amino acids

Also Published As

Publication number Publication date
UA107684C2 (xx) 2015-02-10
NZ600305A (en) 2014-01-31
DOP2012000173A (es) 2012-11-30
HK1171228A1 (en) 2013-03-22
US20110152334A1 (en) 2011-06-23
AU2010340039B2 (en) 2014-03-20
DK2516406T3 (da) 2013-10-14
US8318184B2 (en) 2012-11-27
TW201144290A (en) 2011-12-16
BR112012017188A8 (pt) 2016-10-04
EP2516406A1 (en) 2012-10-31
ES2435651T3 (es) 2013-12-20
CN102695701A (zh) 2012-09-26
MY160618A (en) 2017-03-15
TN2012000281A1 (en) 2013-12-12
WO2011084437A1 (en) 2011-07-14
SG181836A1 (en) 2012-08-30
HN2012001160A (es) 2015-08-24
CY1114880T1 (el) 2016-12-14
JP5779190B2 (ja) 2015-09-16
KR101395356B1 (ko) 2014-05-14
MA33824B1 (fr) 2012-12-03
EA020229B1 (ru) 2014-09-30
EP2516406B1 (en) 2013-09-18
JP2013514974A (ja) 2013-05-02
MX2012007332A (es) 2012-07-20
AU2010340039A1 (en) 2012-08-09
AR079343A1 (es) 2012-01-18
RS53063B (sr) 2014-04-30
CA2784667A1 (en) 2011-07-14
ECSP12011989A (es) 2012-07-31
PH12012501253A1 (en) 2014-08-01
PT2516406E (pt) 2013-10-10
PL2516406T3 (pl) 2014-03-31
CR20120322A (es) 2012-07-10
PE20121688A1 (es) 2012-12-05
HRP20131052T1 (hr) 2013-12-06
KR20120094056A (ko) 2012-08-23
JO2978B1 (en) 2016-03-15
CA2784667C (en) 2014-11-18
IL220011A (en) 2014-03-31
BR112012017188B1 (pt) 2021-06-22
TWI477490B (zh) 2015-03-21
SI2516406T1 (sl) 2013-11-29
EA201290558A1 (ru) 2012-12-28
IL220011A0 (en) 2012-07-31
BR112012017188A2 (pt) 2016-03-22

Similar Documents

Publication Publication Date Title
CN102695701B (zh) Mglu2激动剂
CA2409819C (en) Triazole derivatives
AU2018258355B2 (en) Modulators of sestrin-gator2 interaction and uses thereof
JP2014505660A (ja) 造影剤誘発性腎症の処置方法
JP2018508478A (ja) 疾患の治療のためのｋｄｍ１ａ阻害剤
TW201348239A (zh) 環狀橋頭醚ｄｇａｔ１抑制劑
TW202003472A (zh) 鈣蛋白酶(calpain)調節劑及其醫療用途
JP2022519771A (ja) ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物
TW201627302A (zh) 經取代之醯胺化合物
US7449462B2 (en) Triazole derivatives which inhibit vasopressin antagonistic activity
US9296710B2 (en) Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist
HK1171228B (en) Mglu2 agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant